Six weeks ago QuantuMDx produced a prototype handheld molecular diagnostic device that will provide a DNA-based diagnostic and drug resistance test result in less than half an hour. This milestone heralded a new phase in our company; with this new phase comes new goals and a new partner.
Our focus now is to bring our turnaround time down to less than 20 minutes. We expect to achieve this by optimising chemistries for our new handheld prototype by early next year. This will truly represent a remarkable advance in molecular diagnostic platform technology, and one we are eager to get into the hands of those who need it most.
With this in mind, we’re proud to announce that we’re partnering with Gates-backed international NGO the Foundation for Innovative New Diagnostics (FIND). With FIND’s extensive knowledge of distribution, regulations and on-the-ground requirements for medical devices, this partnership will help guide QuantuMDx as we transition from an R&D organization to a commercial company.
This partnership is an important validation of QuantuMDx’s vision and technology. Since the company’s time in Cape Town, it has been our aim to eliminate the challenges faced by health workers everyday such as inaccurate or unreliable tests, long waiting times during which patients would wander, and the inability to conduct drug susceptibility testing. To be selected as a partner to FIND after their years of screening point of care technologies is an honour, and further strengthens our commitment to delivering the future of diagnostics.